PRELUDE THERAPEUTICS INC

PRLD ·Healthcare, Drug Manufacturers - General, United States
Financial Statements SEC Filings

SEC Filings

Form Filed Description
8-K Apr 21, 2026 8-K
424B5 Apr 21, 2026 424B5
8-K Apr 20, 2026 8-K
3 Apr 15, 2026
8-K Apr 15, 2026 8-K
3 Mar 19, 2026
8-K Mar 12, 2026 8-K
424B5 Mar 12, 2026 424B5
S-8 Mar 10, 2026 S-8
10-K Mar 10, 2026 10-K
8-K Mar 10, 2026 8-K
SCHEDULE 13G/A Feb 13, 2026
4 Feb 5, 2026 PRIMARY DOCUMENT
4 Feb 5, 2026 PRIMARY DOCUMENT
4 Feb 5, 2026 PRIMARY DOCUMENT
4 Feb 5, 2026 PRIMARY DOCUMENT
8-K Feb 3, 2026 8-K
8-K Jan 9, 2026 8-K
EFFECT Dec 16, 2025
CORRESP Dec 15, 2025
S-3 Dec 10, 2025
10-Q Nov 12, 2025 10-Q
8-K Nov 12, 2025 8-K
4 Nov 7, 2025 PRIMARY DOCUMENT
SCHEDULE 13G Nov 7, 2025
← Newer Page 2 of 16 · 389 filings Older →